Premium
HLA‐DR restriction‐fragment‐length polymorphisms in narcolepsy
Author(s) -
Holloman J. D.,
Bell J. I.,
Kilduff T. S.,
Dement W. C.,
Guilleminault C.,
McDevitt H. O.
Publication year - 1987
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.490180134
Subject(s) - restriction fragment length polymorphism , narcolepsy , restriction enzyme , genetics , terminal restriction fragment length polymorphism , restriction fragment , biology , polymorphism (computer science) , allele , genotype , gene , neuroscience , neurology
Seventeen white patients from the Stanford Sleep Disorders Clinic compaining of excessive daytime somnolence (EDS) were selected for restriction‐fragment‐length polymorphism (RFLP) studies. Fourteen of the patients with clinically diagnosed narcolepsy were seropositive for DR2. RFLP analysis of these patients compared with a homozygous DR2‐Dw2 cell line failed to reveal any polymorphism when digested with six restriction endonucleases and hybridized with three different cDNA probes. None of the three patients with central nervous system hypersomnia, a syndrom similar to narcolepsy, were DR2‐positive. We conclude that any polymorphism of the DRβ, DQα or DQβ, genes of DR2 narcoleptics that might distinguish them from DR2 nomals cannot be resolved through RELP analysis.